Eric Aguiar, M.D.
Dr. Aguiar has been a member of our Board of Directors since September 2010. He has been a partner at Aisling Capital, an investment firm specializing in products, technologies, and global businesses that advance health since January 2016. Prior to Aisling Capital, from October 2007 to December 2015, he was a partner at Thomas, McNerney & Partners, a healthcare venture capital and growth equity firm. From 2001 to 2007, Dr. Aguiar was a managing director of HealthCare Ventures, a healthcare focused venture capital firm. He was chief executive officer and a director of Genovo, Inc., a biopharmaceutical company focused on gene delivery and gene regulation, from 1998 to 2000. Since December 2020, he has served as a director of Biomea Fusion, Inc., a preclinical-stage biopharmaceutical company. Additionally, he has served as a director of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company since 2019. Dr. Aguiar previously served as a director of Eidos Therapeutics, Inc. in addition to Biohaven Pharmaceutical Holding Company Ltd. and Amarin Pharmaceuticals, each a public biopharmaceutical company, as well as on the boards of directors of numerous private companies including companies in the life sciences industry. Since September 2021, Dr. Aguiar has served as a director of Garuda Therapeutics, a company focused on developing blood stem cell therapies. He is also a member of the Council on Foreign Relations. Dr. Aguiar received an M.D. with honors from Harvard Medical School and a B.A. in Arts and Sciences from Cornell University. Dr. Aguiar was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar is qualified to serve on our Board of Directors due to his extensive experience with life sciences companies.